Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma

Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been approved in the US and Europe for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib has demonstrated a 44% increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jen-Jung, Javle, Milind, Thinn, Mie Mie, Hsueh, Chung-Tzu, Hsueh, Chung-Tsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846497/
https://www.ncbi.nlm.nih.gov/pubmed/24367212
http://dx.doi.org/10.2147/HMER.S7123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846497/
https://www.ncbi.nlm.nih.gov/pubmed/24367212
http://dx.doi.org/10.2147/HMER.S7123

Ejemplares similares